BridgeMD
Tests treatment safety and results for Mayer Rokitansky Kuster Hauser Syndrome
Official title Feasibility Study of Uterine Transplantation From Living Donors in Terms of Efficacy and Safety in Patients With Mayer-Rokitansky-Küster-Hauser Syndrome (MRKH)
ClinicalTrials.gov ID: NCT03689842
What this study is testing
- What it's testing
- In France, one in 4500 women is affected by the MayerRokitantskyKüsterHauser (MRKH) syndrome which is characterized by the absence of uterus at birth. Currently, the only solutions for these patients are: Gestational surrogacy, prohibited in France Adoption Resignation Uterine transplantation could become a good alternative.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65, women only. Healthy volunteers may be eligible.
You may be able to join if
- Graft recipient is a patient with Mayer-Rokitansky-Küster-Hauser Type I Uterine Vaginal Agenesis (without renal, cardiac and bone malformations):
- Being aged between 18 and 38 years old
- In stable couple, with a pregnancy project, favorable psychological evaluation
- No history of cancer and transfusion The living donor is a woman related to the Graft recipient with
- Absence of comorbidity (neurological, nephro-urological pathology, infectious, psychiatric or psychological pathology)
You likely can't join if
- Graft recipient:
- Extreme oligo-astheno-spermia and azoospermia in the husband
- History of abdominopelvic surgery excluding uncomplicated appendectomy; vaginal residue not allowing anastomosis Living donor :
- Known thromboembolic risk factor
- No Compatibility with the recipient (group, rhesus, HLA)
See the full eligibility criteria
- Graft recipient is a patient with Mayer-Rokitansky-Küster-Hauser Type I Uterine Vaginal Agenesis (without renal, cardiac and bone malformations):
- Being aged between 18 and 38 years old
- In stable couple, with a pregnancy project, favorable psychological evaluation
- No history of cancer and transfusion The living donor is a woman related to the Graft recipient with
- Absence of comorbidity (neurological, nephro-urological pathology, infectious, psychiatric or psychological pathology)
- Absence of uterine surgery, abdomino-pelvic major pathology history
- Graft recipient:
- Extreme oligo-astheno-spermia and azoospermia in the husband
- History of abdominopelvic surgery excluding uncomplicated appendectomy; vaginal residue not allowing anastomosis Living donor :
- Known thromboembolic risk factor
- No Compatibility with the recipient (group, rhesus, HLA)
The study team makes the final eligibility decision.
Where it's taking place
- Suresnes, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 65 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Suresnes, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.